Physician profile
Paul Niolet
NPI 1285837575
$22,966.32
in general payments reported to CMS, 2019-2025
41 companies · $5,842 in 2025
The $5,842 reported for 2025 was more than what 79% of Clinical & Laboratory Immunology (Allergy & Immunology) providers received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $937 · 2021: $2,072 · 2022: $2,968 · 2023: $5,785 · 2024: $3,986 · 2025: $5,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,318 · Consulting Fee: $5,807 · Education: $350 · Travel and Lodging: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,317.67 |
| Consulting Fee | $5,807.44 |
| Education | $349.56 |
| Travel and Lodging | $138.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,939.35 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $3,601.11 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $2,741.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,041.89 | 2019-2025 | Tezspire, Fasenra |
| Csl Behring | $1,408.36 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Pfizer INC. | $909.25 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $900.94 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Genentech USA, INC. | $758.36 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $523.03 | 2019-2025 | |
| Abbvie INC. | $483.20 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $442.05 | 2021-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $431.32 | 2025 | Dawnzera |
| Grifols USA, LLC | $394.80 | 2019-2024 | Xembify |
| Amgen INC. | $326.68 | 2022-2025 | Tezspire |
| Galderma Laboratories, L.P. | $323.36 | 2024-2025 | Nemluvio |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Niolet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.